Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections

Anaerobe

Volumn 15, Issue 6, 2009, Pages 274-280

  McFarland, Lynne V ^a,b  

^a Puget Sound Health Care System   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibiotic associated diarrhea; Clostridium difficile; Lactobacillus; Probiotics; Saccharomyces; Yogurt

Indexed keywords

ANTIBIOTIC AGENT; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; VANCOMYCIN;

ABDOMINAL CRAMP; ARTICLE; ASIA; BACTERIAL STRAIN; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG USE; EUROPE; EVIDENCE BASED MEDICINE; FUNGEMIA; HUMAN; INFECTION; LOW DRUG DOSE; MICROORGANISM; NAUSEA; NONHUMAN; PAIN; PRIORITY JOURNAL; QUALITY CONTROL; RISK BENEFIT ANALYSIS; STANDARDIZATION; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; LACTOBACILLUS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SACCHAROMYCES; TREATMENT OUTCOME;

CLOSTRIDIUM DIFFICILE; LACTOBACILLUS; SACCHAROMYCES;

EID: 70450250081     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2009.09.002     Document Type: Article

References (65)

1. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 16 (1998) 292-307
2. Surawicz C.M. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?. Chemotherapy 51 Suppl. 1 (2005) 81-89
3. McFarland L.V. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 3 (2008 Oct) 563-578
4. Dubberke E.R., Reske K.A., Olsen M.A., McDonald L.C., and Fraser V.J. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis 46 4 (2008) 497-504
5. Song X., Bartlett J.G., Speck K., Naegeli A., Carroll K., and Perl T.M. Rising Economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol (2008 Jul 18)
6. McFarland L.V., Mulligan M.E., Kwok R.Y.Y., and Stamm W.E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320 (1989) 204-210
7. Shek F.W., Stacey B.S., Rendell J., Hellier M.D., and Hanson P.J. The rise of Clostridium difficile: the effect of length of stay, patient age and antibiotic use. J Hosp Infect 45 3 (2000 Jul) 235-237
8. Elixhauser A., and Jhung M. Clostridium difficile-associated disease in U.S. Hospitals, 1993-2005. Statistical brief #50 Available at: (April 2008), Agency for Healthcare Research and Quality. www.hcup-us.ahrq.gov/reports/statbriefs/Sb50.pdf
9. Zilberberg M.D., Shorr A.F., and Kollef M.H. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerging Infect Dis 14 6 (2008 Jun) 929-931
10. McFarland L.V., Clarridge J.E., Beneda H.W., and Raugi G.R. Fluoroquinolone use and risk factors for Clostridium difficile disease within a Veterans Administration Health Care System. Clin Infect Dis 45 9 (2007) 1141-1151
11. Pepin J., Valiquette L., and Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173 9 (2005) 1037-1042
12. McFarland L.V., Surawicz C.M., Rubin M., Fekety R., Elmer G.W., and Greenberg R.N. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 20 (1999) 43-50
13. McFarland L.V., Surawicz C.M., and Stamm W.E. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 162 3 (1990) 678-684
14. Eriksson S., and Aronsson B. Medical implications of nosocomial infection with Clostridium difficile. Scand J Infect Dis 21 6 (1989) 733-734
15. Al Eidan F.A., McElnay J.C., Scott M.G., and Kearney M.P. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharm Ther 25 2 (2000) 101-109
16. Kyne L., Hamel M.B., Polavaram R., and Kelly C.P. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34 3 (2002 Feb 1) 346-353
17. O'Brien J.A., Lahue B.J., Caro J.J., and Davidson D.M. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 28 11 (2007 Nov) 1219-1227
18. McFarland L.V., Beneda H.W., Clarridge J.E., and Raugi G.J. Implications of the changing face of C. difficile disease for health care practitioners. Am J Infect Control 35 4 (2007) 237-253
19. Hoffman F.A., Heimbach J.T., Sanders M.E., and Hibberd P.L. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. Clin Infect Dis 46 Suppl. 2 (2008 Feb 1) S53-S57 PMID: 18181723
20. Elmer G.W., McFarland L.V., and McFarland M. The power of probiotics: improving your health with beneficial microbes. [Chapter 1 Introduction, pages] (2007), Haworth Press, Binghamton, N.Y 1-24
21. Homayouni A., Azizi A., Ehsani M.R., Yarmand M.S., and Razavi S.H. Effect of microencapsulation and resistant starch on the probiotic survival and sensory properties of synbiotic ice cream. Food Chem 111 1 (2008) 50-55
22. Anukam K.C., Osazuwa E.O., Osadolor H.B., Bruce A.W., and Reid G. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. J Clin Gastroenterol 42 3 (2008 Mar) 239-243
23. De Vrese M., and Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 111 (2008) 1-66
24. Kotowska M., Albrecht P., and Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 21 (2005) 583-590
25. Lewis S.J., Potts L.F., and Barry R.E. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 36 (1998) 171-174
26. McFarland L.V., Surawicz C.M., Greenberg R.N., Elmer G.W., Moyer K.A., Melcher S.A., et al. Prevention of β-lactam-associated diarrhea by Saccharomyces boulardii compared to placebo. Am J Gastroenterol 90 (1995) 439-448
27. Hickson M., D'Souza A.L., Muthu N., Rogers T.R., Want S., Rajkumar C., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335 7610 (2007 Jul 14) 80-83
28. McFarland L.V. Meta-analysis of probiotics for prevention of antibiotic associated diarrhea and treatment of Clostridium difficile disease. Am J Gastroenterol 101 (2006) 812-822
29. Meerpohl J.J., and Timmer A. News from the Cochrane Library: probiotics for the prevention of paediatric antibiotic-associated diarrhoea. Z Gastroenterol 45 8 (2007 Aug) 715-717 [PMID: 17701862]
30. Johnston B.C., Supina A.L., Ospina M., and Vohra S. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2 (2007 Apr 18) CD004827
31. Van Niel C.W., Feudtner C., Garrison M.M., and Christakis D.A. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 109 (2002) 678-684
32. Johnston B.C., Supina A.L., and Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 175 4 (2006 Aug 15) 377-383
33. Buts J.P. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci (2008 Jun 5) [epub]
34. Kekkonen R.A., Sysi-Aho M., Seppanen-Laakso T., Julkunen I., Vapaatalo H., Oresic M., et al. Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. World J Gastroenterol 14 20 (2008 May 28) 3188-3194
35. McFarland L.V., Surawicz C.M., and Greenberg R.N. 10 other authors. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271 (1994) 1913-1918
36. Surawicz C.M., McFarland L.V., Greenberg R.N., Rubin M., Fekety R., Mulligan M.E., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31 4 (2000) 1012-1017
37. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 95 S1 (2000) S11-S13
38. Wullt M., Hagslatt M.J., and Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 35 (2003) 365-367
39. Lawrence S.J., Korzenik J.R., and Mundy L.M. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 54 Pt 9 (2005 Sep) 905-906
40. Plummer S., Weaver M.A., Harris J.C., et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of Clostridium difficile diarrhoea. Int Microbiol 7 (2004) 59-62
41. Boyle R.J., et al. Probiotic use in clinical practice: what are the risks?. Am J Clini Nutr 83 (2006) 1256-1264
42. McCullough M.J., Clemons K.V., McCusker J.H., and Stevens D.A. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol 36 9 (1998 Sep) 2613-2617
43. Rautio M., Jousimies-Somer H., Kauma H., Pietarinen I., Saxelin M., Tynkkynen S., et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 28 (1999) 1159-1160
44. Boirivant M., and Strober W. The mechanism of action of probiotics. Curr Opin Gastroenterol 23 6 (2007 Nov) 679-692 [PMID: 17906447]
45. Gu R.X., Yang Z.Q., Li Z.H., Chen S.L., and Luo Z.L. Probiotic properties of lactic acid bacteria isolated from stool samples of longevous people in regions of Hotan, Xinjiang and Bama, Guangxi, China. Anaerobe (2008 Jun 28)
46. McFarland L.V. A review of the evidence of health claims for biotherapeutic agents. Microb Ecol Health Dis 12 (2000) 65-76
47. Frank D.N., and Pace N.R. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 24 1 (2008 Jan) 4-10
48. McFarland L.V. Normal flora: diversity and functions. Microb Ecol Health Dis 12 (2000) 193-207
49. Bruewer M., Luegering A., Kucharzik T., Parkos C.A., Madara J.L., Hopkins A.M., et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171 (2003) 6164-6172
50. Wu X., Vallance B.A., Boyer L., Bergstrom K.S., Walker J., Madsen K., et al. Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol 294 1 (2008 Jan) G295-G306
51. Castagliuolo I., LaMont J.T., Nikulasson S.T., and Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 64 (1996) 5225-5232
52. Buts J.P., Dekeyser N., Stilmant C., Delem E., Smets F., and Sokal E. Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res 60 1 (2006 Jul) 24-29
53. Paton A.W., Jennings M.P., Morona R., Wang H., Focareta A., Roddam L.F., et al. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 128 5 (2005 May) 1219-1228
54. Kyne L., Warny M., Qamar A., and Kelly C.P. Association between antibody response to toxin a and protection against recurrent Clostridium difficile diarrhea. Lancet 357 (2001) 189-193
55. Martin F.P., Wang Y., Sprenger N., Yap I.K.S., Lundsted T., Lek P., et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol 4 (2008) 157 [PMID: 18197175]
56. Verdú E.F., Bercik P., Verma-Gandhu M., Huang X.X., Blennerhassett P., Jackson W., et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55 2 (2006 Feb) 182-190
57. Soo I., Madsen K.L., Tejpar Q., Sydora B.C., Sherbaniuk R., Cinque B., et al. VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol 22 3 (2008 Mar) 237-242
58. Barc M.C., Charrin-Sarnel C., Rochet V., Bourlioux F., Sandré C., Boureau H., et al. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii. Anaerobe (2008 Apr 22) [Epub ahead of print]
59. Gorbach S.L. Probiotics and gastrointestinal health. Am J Gastroenterol 95 Suppl. 1 (2000 Jan) S2-S4
60. Elmer G.W., McFarland L.V., Surawicz C.M., Danko L., and Greenberg R.N. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 13 12 (1999 Dec) 1663-1668
61. Marcobal A., Underwood M.A., and Mills D.A. Rapid determination of the bacterial composition of commercial probiotic products by terminal restriction fragment length polymorphism analysis. J Pediatr Gastroenterol Nutr 46 5 (2008 May) 608-611
62. Doron S., and Gorbach S.L. Probiotics: their role in the treatment and prevention of disease. Expert Rev Anti-Infect Ther 4 2 (2006 Apr) 261-275
63. Jayamanne V.S., and Adams M.R. Determination of survival, identity and stress resistance of probiotic bifidobacteria in bio-yoghurts. Lett Appl Microbiol 42 3 (2006 Mar) 189-194
64. Masco L., Huys G., De Brandt E., Temmerman R., and Swings J. Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria. Int J Food Microbiol 102 2 (2005 Jul 15) 221-230
65. Reid G. How science will help shape future clinical applications of probiotics. Clin Infect Dis 46 Suppl. 2 (2008 Feb 1) S62-S66